Jun 28, 2024 9:00 am EDT Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Jun 25, 2024 8:30 am EDT Capricor Therapeutics Announces Pre-BLA Meeting with FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Jun 11, 2024 9:25 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Jun 04, 2024 9:00 am EDT Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
May 13, 2024 4:05 pm EDT Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 9:15 am EDT Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
May 08, 2024 9:00 am EDT Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
May 06, 2024 9:00 am EDT Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Apr 24, 2024 9:00 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy